Key result
3D cardiac fibrosis-on-a-chip replicates post-MI architecture with ~48% higher myofibroblast activation in scar regions.
Answers are grounded in this paper and cite their sources.
The developed cardiac fibrosis-on-a-chip model provides a physiologically relevant system for investigating immune-mediated fibrosis and therapeutic screening in fibrotic heart disease.
. TGF-β was used as a comparative biochemical stimulus to establish baseline fibrotic signaling. Immunostaining and computational modeling confirmed the spatial patterning of CM/CF and macrophage gradient distribution. This cardiac fibrosis-on-a-chip model provides an innovative and physiologically relevant system to investigate immune-mediated fibrosis. It enables region-specific analysis of immune-cardiac interactions and serves as a valuable model for therapeutic screening in fibrotic heart disease.
No takes yet. Share an insight, caveat, or question.
Ji et al. (2025) studied Cardiac fibrosis following myocardial infarction. Immune-integrated cardiac fibrosis-on-a-chip vs. 2D cardiac fibrosis model was evaluated on Ratio of alpha-SMA to vimentin (myofibroblast activation) (p=<0.01). The 3D cardiac fibrosis-on-a-chip model successfully replicated region-specific post-MI tissue architecture and demonstrated a higher alpha-SMA to vimentin ratio in the scar region compared to healthy sections.
Synapse has enriched 10 related papers. Consider them for comparative context: